Physician
Oncology
Dr. Julie A. Ellerhorst, MD
Julie A. Ellerhorst, MD is an expert in the field of Oncology. Julie Ellerhorst is a published MD. She has 64 publications published. The most current publication "Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1."
Publications
- Expression of Leptin and iNOS in Oral Melanomas in Dogs.
- Association of activated c-Met with NRAS-mutated human melanomas: A possible avenue for targeting.
- Clinical correlates of NRAS and BRAF mutations in primary human melanoma.
- Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.
- Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma.
- NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.
- Lack of maturation with anti-leptin receptor antibody in melanoma but not in nevi.
- Tumor iNOS predicts poor survival for stage III melanoma patients.
- Expression of thyrotropin-releasing hormone by human melanoma and nevi.
- Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy.
- Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression ...
- Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
- Loss of MDA-7 expression with progression of melanoma.
- Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP.
- MDA-7/IL-24 is a unique cytokine--tumor suppressor in the IL-10 family.
- Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma.
- Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer.
- Constitutive intracellular production of iNOS and NO in human melanoma: possible role in regulation of growth and resistance to apoptosis.
- Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer.
- Absence of antitumor activity with prednisone in patients with progressive androgen-independent prostate carcinoma.
- Paclitaxel in extensively pretreated nonseminomatous germ cell tumors.
- Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate.
- Galectin-1 and galectin-3 expression in human prostate tissue and prostate cancer.
- Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas.
- Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
- Phase II evaluation of bryostatin-1 in metastatic melanoma.
- Whole brain irradiation for patients with metastatic melanoma: a review of 87 cases.
- Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival.
- A phase II evaluation of bexarotene (Targretin) capsules in patients with metastatic melanoma.
- Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.
- Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
- Carboplatin and ifosfamide and selective consolidation in advanced seminoma.
- Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for ...
- A phase I trial of intermittent high-dose alpha-interferon and dexamethasone in metastatic renal cell carcinoma.
- 5-Fluorouracil and interferon-alpha in chemotherapy refractory bladder carcinoma: an effective regimen.
- Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin.
- Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.
- Hyperplasia of axillary nodes in patients undergoing immunotherapy.
- Effect of decreased plasma low-density lipoprotein levels on adrenal and testicular function in man.
- Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1.
- Differential expression of endogenous galectin-1 and galectin-3 in human prostate cancer cell lines and effects of overexpressing galectin-1 on cell phenotype.
- Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
- Intraabdominal desmoplastic small cell tumor. Report and discussion of five cases.
- Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature.
- Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
- Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma.
- 2''-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.
- Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: re...
- Factors affecting the insulin autoantibody ELISA.
- Protamine antibody production in diabetic subjects treated with NPH insulin.
- A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.
- Melanoma metastatic to the spine: a review of 133 cases.
- Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.
- Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.
- High prevalence of hypothyroidism among patients with cutaneous melanoma.
- HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.
- Autoimmunity and hypothyroidism in patients with uveal melanoma.
- Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.
- Promotion of melanoma growth by the metabolic hormone leptin.
- Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
- A phase I study of FAP (5-Fluorouracil, ?-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies.
- Human melanoma cells express functional receptors for thyroid-stimulating hormone.
- Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.
Schools
Baylor University
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Helpful Reviews
Similar Doctors
|
Dr. Frankie A. Holmes, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Karen L. Cottingham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Benjamin Musher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mothaffar F. Rimawi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas P. Haynie III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanwal P. Raghav, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Zehra Kapadia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alessandra Ferrajoli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paulo M. Hoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Werner A. Bleyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Filip Janku, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|